Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients. Dabigatran is introduced into clinical practice, although many issues regarding this drug are sti...
Main Authors: | Josef Finsterer, Claudia Stöllberger |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2012-02-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/5/2/155/ |
Similar Items
-
PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015-09-01) -
Possibility of using dabigatran in patients with atrial fibrillation and acute coronary syndrome and PCI
by: A. D. Erlich
Published: (2019-04-01) -
Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
by: A.V. Fonyakin
Published: (2014-06-01) -
Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance
by: Hiroshi Inoue, et al.
Published: (2016-04-01) -
Reliability and safety of long-term dabigatran use in patients with atrial fibrillation
by: E. V. Serdechnaya, et al.
Published: (2013-04-01)